The Open Group Related Exams
OG0-093 Exam
The Open Group OG0-093 exam assesses your knowledge across all aspects of TOGAF 9, including:
The Open Group OG0-093 and OG0-091 exams are both part of The Open Group's TOGAF certification program, but they serve different purposes:
Scenario
Please read this scenario prior to answering the Question
You are serving as the Lead Architect for an enterprise architecture project team within a leading multinational pharmaceutical and medical devices manufacturer. Its brands include numerous household names for medications and first aid supplies.
The company has a long history of innovating new treatments for many common illnesses and diseases. Prior to launching a new treatment, the company has to demonstrate Its effectiveness and safety in a set of clinical trials that satisfy the regulatory requirements of the countries in the target markets. All clinical trials are undertaken by its research laboratories, which employ over 10,000 people at separate facilities in the United Kingdom, United States, Sweden, France, Canada, India, China and Japan. In addition to internal research and development activities the company is also involved in publicly funded collaborative research projects, with other industrial and academic partners.
The Enterprise Architecture group within the company has been engaged in an architecture development project to create a secure networked collaboration system that will allow researchers at its product development laboratories worldwide to share information about their clinical trials. This system will also connect with external partners.
The Enterprise Architecture group within the company has been engaged in an architecture development project to create a secure networked collaboration system that will allow researchers at its product development laboratories worldwide to share information about their clinical trials. This system will also connect with external partners.
The Enterprise Architecture group is a mature organization. They use the TOGAF 9 ADM with extensions required to support current good manufacturing practices and good laboratory practices in their target markets. Due to the highly sensitive nature of the information that is managed, special care was taken to ensure that each architecture domain included an examination of the security and privacy issues that are relevant.
The Executive Vice President for Clinical Research is the sponsor of the Enterprise Architecture activity. She has stated that the changes to the enterprise architecture for the new system will need to be rolled out in stages on a regional basis that minimizes disruptions to ongoing clinical trials.
Refer to the Scenario
You have been asked to recommend the approach to identify the work packages that will be included in the Transition Architecture(s).
Based on TOGAF, which of the following is the best answer?
Please read this scenario prior to answering the question.
You are employed as an Enterprise Architect within an Enterprise Architecture team at a large food services company.
The company has a mature EA practice and uses the TOGAF standard for its architecture work. In addition to using the TOGAF standard, the company uses a number of management frameworks, including project management and operations management. The Chief Information Officer is the sponsor of the EA program within the company.
The company focuses on sales to trade and wholesale customers, for example, restaurants and other food sellers. It sells a variety of products and serves a number of different markets. One of the company’s rivals has launched a competing product range and additional services. They are running a widespread advertising campaign with generous rewards for customers to switch to them. Many of the company’s customers have announced that they are changing to the rival.
The Chief Executive Officer has stated that changes need to be made to address the situation. He wants new markets to be found for the company’s products. The business needs to change direction and address the retail market as well as the existing market.
The company is accustomed to a stable business with a well-established and consistent customer base. It is uncertain whether the company will be able to adapt to changes in its business practices, and whether these changes will be temporary or permanent. The company’s culture presents a potential risk factor.
You have been working with the sales, logistics, production, and marketing teams, enabling the architecture development activity to start. An Architecture Vision, Architecture Principles, and Requirements have all been agreed. As you move forward to develop a possible Target Architecture, you have identified that some of the key stakeholders’ preferences are incompatible. The incompatibilities are focused on time-to-market, cost savings, and the need to bring out a fully featured range of products, but there are additional factors.
Refer to the scenario.
How should you address the incompatibilities between key stakeholder preferences?
Based on the TOGAF standard, which of the following is the best answer?
Scenario
Please read this scenario prior to answering the Question
You have been appointed as a consultant to the Chief Enterprise Architect of a multinational pharmaceutical corporation. The corporation includes 30 subsidiary companies with operations in over 60 countries and products sold in over 125 countries. It has major research and development sites in over 45 locations worldwide.
The management team is deeply committed to ensuring that the corporation is a world leader in socially responsible pharmaceutical development with a business strategy that focuses on profitability through environmentally friendly operating processes as well as a commitment to disease eradication.
The operations of the corporation are subject to legal and regulatory requirements for each country where they operate. The production of prescription pharmaceutical products has governmental controls that are strictly enforced and compliance is critical. Recently a competitor was heavily fined for violating the regulations in a country where it was conducting a clinical trial for a new regulated drug.
The Governing Board is concerned about the risks posed in this complex global environment. As a result the Chief Executive Officer (CEO) has appointed a Chief Compliance Officer (CCO) to be responsible for overseeing and managing compliance issues for the corporation. The CCO reports directly to the CEO.
The CCO has approved the expenditure of resources to establish an Enterprise Architecture program. He has requested to be informed about the status of projects that could impact regulatory compliance. He also wants the corporate legal staff and auditors to analyze all proposed architectures to ensure that they are within the legal guidelines for each country. In addition, the research organization should be able to see that the architecture is appropriate for its needs.
TOGAF 9 has been mandated as the framework for the development and evolution of the Enterprise Architecture practice. The Preliminary Phase has been completed to establish the enterprise architecture capability for this project.
Refer to the Scenario
You have been asked to recommend an approach that would enable the development of an architecture that addresses the needs of the Chief Compliance Officer, legal staff, auditors and the research organization.
Based on TOGAF, which of the following is the best answer?